SEC Comment Letter 0000000000-25-002977 to Evaxion A/S (EVAX)
Evaxion A/S
Date: March 19, 2025 · CIK: 0001828253 · Accession: 0000000000-25-002977
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285778
Letter
Re: Evaxion Biotech A/S Registration Statement on Form F-3 Filed March 13, 2025 File No. 333-285778 Dear Christian Kanstrup:
March 19, 2025
Christian Kanstrup Chief Executive Officer Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 H rsholm Denmark
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Michael D. Baird, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 19, 2025 Christian Kanstrup Chief Executive Officer Evaxion Biotech A/S Dr. Neergaards Vej 5F 2970 H rsholm Denmark Re: Evaxion Biotech A/S Registration Statement on Form F-3 Filed March 13, 2025 File No. 333-285778 Dear Christian Kanstrup: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael D. Baird, Esq. </TEXT> </DOCUMENT>